Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer

BMC Cancer

Akira Ooki¹  Keishi Yamashita¹  Shiro Kikuchi¹  Shinichi Sakuramoto¹  Natsuya Katada¹  Mina Waraya¹  Hiroshi Kawamata¹  Hiroshi Nishimiya¹  Kazunori Nakamura¹  Masahiko Watanabe¹ 

[1] Department of Surgery, Kitasato University Hospital, Kitasato 1-15-1, Sagamihara 228-8555, Kanagawa, Japan

关键词: lymph node;    targeted therapy;    genomic amplification;    gastric cancer;    PRL-3;   

Others  :  1081013
DOI  :  10.1186/1471-2407-11-122

 received in 2010-09-26, accepted in 2011-04-06,  发布年份 2011

【 摘 要 】

Background

Phosphatase of regenerating liver-3 (PRL-3) has deserved attention as a crucial molecule in the multiple steps of metastasis. In the present study, we examined the mechanisms regulating PRL-3 expression, and assessed the clinical potential of PRL-3-targeted therapy in gastric cancer.

Methods

PRL-3 genomic amplification was analyzed using quantitative-polymerase chain reaction and/or fluorescence in situ hybridization in 77 primary gastric tumors. The anticancer activity of PRL-3 inhibitor (1-4-bromo-2-benzylidene rhodanine) treatment was evaluated against cancer cells with different genetic and expression status.

Results

PRL-3 genomic amplification was closely concordant with high level of its protein expression in cell lines, and was found in 20% (8/40) among human primary tumors with its expression, which were all stage III/IV disease (40%, 8/20), but in none (0/37) among those without expression. Additionally, PRL-3 genomic amplification was associated with metastatic lymph node status, leading to advanced stage and thereby poor outcomes in patients with lymph node metastasis (P = 0.021). PRL-3 small interfering RNA robustly repressed metastatic properties, including cell proliferation, invasion, and anchorage-independent colony formation. Although neither PRL-3 genomic amplification nor expression level was responsible for the sensitivity to PRL-3 inhibitor treatment, the inhibitor showed dose-dependent anticancer efficacy, and remarkably induced apoptosis on all the tested cell lines with PRL-3 expression.

Conclusions

We have for the first time, demonstrated that PRL-3 genomic amplification is one of the predominant mechanisms inducing its expression, especially in more advanced stage, and that PRL-3-targeted therapy may have a great potential against gastric cancer with its expression.

【 授权许可】

   
2011 Ooki et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Crew KD, Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol 2006, 12(3):354-362.
• [2]Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer 2004, 4:448-456.
• [3]Bessette DC, Qiu D, Pallen CJ: PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev 2008, 27:231-252.
• [4]Zeng Q, Si X, Horstmann H, Xu Y, Hong W, Pallen CJ: Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. J Biol Chem 2000, 275(28):21444-21452.
• [5]Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, et al.: A phosphatase associated with metastasis of colorectal cancer. Science 2001, 294(5545):1343-1346.
• [6]Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M: Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer. Oncol Rep 2009, 21(6):1467-1475.
• [7]Guo K, Li J, Wang H, Osato M, Tang JP, Quah SY, Gan BQ, Zeng Q: PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. Cancer Res 2006, 66(19):9625-9635.
• [8]Song R, Qian F, Li YP, Sheng X, Cao SX, Xu Q: Phosphatase of regenerating liver-3 localizes to cyto-membrane and is required for B16F1 melanoma cell metastasis in vitro and in vivo. PLoS One 2009, 4(2):e4450.
• [9]Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, Pallen CJ, Manser E, Hong W: PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 2003, 63(11):2716-2722.
• [10]Albertson DG: Gene amplification in cancer. Trends Genet 2006, 22(8):447-455.
• [11]Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M: Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma. Int J Cancer 2010, 127(3):543-554.
• [12]Lauren P: The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. an Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand 1965, 64:31-49.
• [13]Dote H, Toyooka S, Tsukuda K, Yano M, Ota T, Murakami M, Naito M, Toyota M, Gazdar AF, Shimizu N: Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Cancer 2005, 92(6):1117-1125.
• [14]Nozue M, Nishida M, Todoroki T, Iwasaki Y: Establishment and characterization of a human scirrhus type gastric cancer cell line, GCIY, producing CA19-9. Hum Cell 1991, 4(1):71-75.
• [15]Yokozaki H: Molecular characteristics of eight gastric cancer cell lines established in Japan. Pathol Int 2000, 50(10):767-777.
• [16]Ahn JH, Kim SJ, Park WS, Cho SY, Ha JD, Kim SS, Kang SK, Jeong DG, Jung SK, Lee SH, et al.: Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. Bioorg Med Chem Lett 2006, 16(11):2996-2999.
• [17]Mizuuchi E, Semba S, Kodama Y, Yokozaki H: Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression. Int J Cancer 2009, 124(8):1802-1810.
• [18]Association JGC: Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998, 1(1):10-24.
• [19]Nakajima T: Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002, 5(1):1-5.
• [20]Sobin LH: TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol 2003, 21(1):19-22.
• [21]Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145.
• [22]Baehner FL, Achacoso N, Maddala T, Shak S, Quesenberry CP Jr, Goldstein LC, Gown AM, Habel LA: Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 2010, 28(28):4300-4306.
• [23]Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitaitve PCR and the 2(-Delta Delata C(T)) Method. Methods 2001, 25:402-408.
• [24]Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, et al.: Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood 2007, 111:806-815.
• [25]Wang Z, He YL, Cai SR, Zhan WH, Li ZR, Zhu BH, Chen CQ, Ma JP, Chen ZX, Li W, et al.: Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference. Int J Cancer 2008, 123(6):1439-1447.
• [26]Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR: Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 2009, 28:2796-2805.
• [27]Wang Z, Cai SR, He YL, Zhan WH, Chen CQ, Cui J, Wu WH, Wu H, Song W, Zhang CH, et al.: High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients. Ann Surg Oncol 2009, 16(1):208-219.
• [28]Matter WF, Estridge T, Zhang C, Belagaje R, Stancato L, Dixon J, Johnson B, Bloem L, Pickard T, Donaghue M, et al.: Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling. Biochem Biophys Res Commun 2001, 283(5):1061-1068.
• [29]Siewert JR, Bottcher K, Stein HJ, Roder JD: Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998, 228(4):449-461.
• [30]Basak S, Jacobs SB, Krieg AJ, Pathak N, Zeng Q, Kaldis P, Giaccia AJ, Attardi LD: The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell 2008, 30(3):303-314.
• [31]Jiang Y, Liu XQ, Rajput A, Geng L, Ongchin M, Zeng Q, Taylor GS, Wang J: Phosphatase PRL-3 Is a Direct Regulatory Target of TGF{beta} in Colon Cancer Metastasis. Cancer Res 2010, 71(1):234-244.
• [32]Wang H, Vardy LA, Tan CP, Loo JM, Guo K, Li J, Lim SG, Zhou J, Chng WJ, Ng SB, et al.: PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell 2010, 18(1):52-62.
• [33]Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, et al.: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005, 23(31):8081-8092.
• [34]Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Lohrs U: Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001, 19(2):354-363.
• [35]Daouti S, Li WH, Qian H, Huang KS, Holmgren J, Levin W, Reik L, McGady DL, Gillespie P, Perrotta A, et al.: A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res 2008, 68(4):1162-1169.